US2012202977A1PendingUtilityA1

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor

Assignee: SILENCE KARENPriority: Nov 8, 2002Filed: Mar 19, 2012Published: Aug 9, 2012

Est. expiryNov 8, 2022(expired)· nominal 20-yr term from priority

Inventors:Karen Silence Marc Jozef Lauwereys Hans De Haard

A61P 31/00A61P 31/04A61P 37/06A61P 35/00C07K 2317/34C07K 2317/31C07K 2317/24C07K 2317/92C07K 2317/76C07K 2319/00C07K 16/2875C07K 2317/569C07K 16/4291C07K 16/40A61K 2039/505C07K 16/36C07K 2317/22A61P 19/02C07K 16/241C07K 2317/565C07K 16/18C07K 2317/626C07K 16/249C07K 16/2863C07K 2317/567

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.

Claims

exact text as granted — not AI-modified

1 . A polypeptide comprising (i) first and second heavy chain single variable domains or (ii) first and second light chain single variable domains, the domains having the same epitope specificity, wherein the epitope is provided as multiple copies by TNF-alpha. 
     
     
         2 . The polypeptide according to  claim 1 , wherein the variable domains are provided by an antibody scFv fragment. 
     
     
         3 . The polypeptide according to  claim 1 , wherein the variable domains are provided by an antibody Fab region. 
     
     
         4 . The polypeptide of  claim 1 , wherein the or each variable domain is a Camelid VHH domain.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.